Hivid


Also found in: Dictionary, Thesaurus.
Related to Hivid: Rescriptor, Zerit, Agenerase

Hivid

Zalcitabine, see there. See AIDS, ddC.
References in periodicals archive ?
children/adolescents with HIV Combination ART use -50% Hivid use +80% Retrovir use +90% Figure 1.
Alternative recommendations COLUMN A COLUMN B Agenerase Retrovir plus Hivid Fortovase Videx plus Epivir Norvir Rescriptor Viracept plus Fortovase Viramune Ziagen
Nucleoside Analogue Reverse Transcriptase Inhibitors Generic Name Initials Trade Name Manufacturer Didanosine (1990) ddl Videx Bristol-Myers Squibb Lamivudine (1995) 3TC Epivir Glaxo Wellcome Stavudine (1994) d4T Zerit Bristol-Myers Squibb Zalcitabine (1992) ddC HIVID Hoffmann-LaRoche Zidovudine (1987) AZT/ZDV Retrovir Glaxo Wellcome Table 2.
[ILLUSTRATION OMITTED] TABLE: Currently approved medications for treating HIV/AIDS Protease Entry Nukes Non-nukes Inhibitors Inhibitors Combivir Rescriptor Agenerase Fuzeon (Epivir + Retrovir) Emtriva Sustiva Crixivan Epivir Viramune Fortovase Hivid Invirase Retrovir Kaletra Trizivir (Epivir + Lexiva Retrovir + Ziagen) Videx (regular or EC) Norvir Viread Reyataz Zerit Viracept Ziagen
Didanosine is not recommended for use with zalcitabine (Hivid).
HIV disease itself and drugs such as Videx (ddl), Zerit (d4T), and Hivid (ddC)--the "d drugs"--are known to cause "distal symmetric peripheral neuropathy" (DSPN).
Zalcitabine is supplied in 0.750 mg tablets (shown) that are oval, gray, film-coated and imprinted with "HIVID 0.750" on one side and "Roche" on the other side.
These drugs include Videx, Zerit, Hivid, Retrovir, Epivir, and Ziagen.
Because additive neurotoxicity is possible, stavudine should not be combined with zalcitabine (Hivid).
* ACTG A5157: This study will look at the effectiveness of acetyl-L-carnitine for the treatment of peripheral neuropathy associated with certain anti-HIV drugs like Videx, Zerit, and Hivid. To participate in this study, you must be experiencing symptoms such as pain in the feet or legs, with the pain starting or worsening within 12 months of taking of any of those drugs.
Early trials studied saquinavir as monotherapy, in combination with zidovudine (Retrovir) and zalcitabine (Hivid) and in high doses.
The 14 patients were taking nucleoside reverse transcriptase inhibitors (NRTIs), a family of anti-HIV drugs that includes ddl, d4T, ddC (Hivid), 3TC (Epivir), AZT (Retrovir), and abacavir (Ziagen).